Nasal Resveratrol and Wheezing Episodes in Preschool Children
RSVchild
Intermittent Treatment With Nasal Resveratrol and Reduction of Wheezing Episodes in Non Atopic Preschool Children
1 other identifier
observational
50
1 country
1
Brief Summary
As most of the upper airways infections (UAI) leading to wheezing are secondary to viral triggers, the possible antinflammatory and antiviral role of resveratrol has been suggested in several studies, both in vitro and in vivo. However, its efficacy has been studied only when evaluating upper respiratory symptoms. With the aim to define new approaches in patients with recurrent wheezing triggered by UAI we have performed a prospective observational study to evaluate the efficacy of a short-course of intranasal resveratrol, administered for 7 days at the beginning of UAI, when compared to standard nasal lavage with 0.9% saline solution, in terms of reduction in wheezing episodes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2019
CompletedFirst Submitted
Initial submission to the registry
December 27, 2020
CompletedFirst Posted
Study publicly available on registry
December 30, 2020
CompletedDecember 30, 2020
December 1, 2020
12 months
December 27, 2020
December 27, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
Wheezing days
number of wheezing days during the follow-up period
october 2017 - march 2018
Secondary Outcomes (2)
Severity index
october 2017 - march 2018
Severity index
october 2017 - march 2018
Study Arms (2)
Cases
Children spontaneously treated with nasal resveratrol at the beginning of each upper airways infection
Controls
Children spontaneously treated with nasal lavage at the beginning of each upper airways infection
Interventions
Eligibility Criteria
Patients were selected from those referring to our centre for recurrent wheezing in the previous year.
You may qualify if:
- Presence of at least 8 episodes of wheezing in the previous October-March period
- Negative skin prick test (SPT) for the most common allergens.
- Age less than 6 years
You may not qualify if:
- Sensitization to food allergens
- Sensitization to perennial allergens or to tree pollen allergens.
- Presence of atopic dermatitis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Università di Perugia
Perugia, 06100, Italy
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Giuseppe Di Cara
Study Record Dates
First Submitted
December 27, 2020
First Posted
December 30, 2020
Study Start
April 1, 2018
Primary Completion
March 31, 2019
Study Completion
April 30, 2019
Last Updated
December 30, 2020
Record last verified: 2020-12
Data Sharing
- IPD Sharing
- Will not share